Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
ApexOnco Front Page
Recent articles
A pipeline update reveals the dropping of RC248, after cMet and Claudin18.2 ADCs disappeared earlier.
Results with eftilagimod alpha in first-line head and neck cancer threaten to cloud partnering prospects.
Other projects new to the clinic include Haisco’s USP1 inhibitor and and Avistone’s type II c-MET blocker.
Checkmate-9DW scores a topline win on overall survival, when failure seemed more likely.
The drug adds a new use to its US label, but Takeda’s 2017 Ariad acquisition still looks expensive.
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Carvykti sailed through Friday’s adcom, but Abecma got a much rougher ride.